Related Experiment Video
Updated: Oct 23, 2025
10:22
Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
3.7K
Update on omalizumab in allergen immunotherapy
Jennifer A Dantzer1, Robert A Wood
1Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Current Opinion in Allergy and Clinical Immunology
|August 22, 2021
Summary
Omalizumab combined with allergen immunotherapy may speed up treatment and reduce side effects for allergies. However, severe reactions can still occur, and long-term risks after stopping omalizumab require further study.
Area of Science:
- Immunology
- Allergy Research
- Pharmacology
Background:
- Omalizumab is a monoclonal antibody used in treating allergic diseases.
- Allergen immunotherapy (AIT) aims to desensitize patients to allergens.
- Combining omalizumab with AIT is an emerging therapeutic strategy.
Purpose of the Study:
- To review current studies on omalizumab's role in allergen immunotherapy.
- To assess the efficacy and safety of this combination therapy.
Main Methods:
- Literature review of relevant clinical studies.
- Analysis of data on treatment duration, adverse events, and long-term outcomes.
Main Results:
- Omalizumab may shorten the time to reach maintenance dosing in AIT.
- Combination therapy appears to reduce adverse events associated with AIT.
- Severe adverse events are still possible, and long-term data is limited.
- Potential for increased reactivity after omalizumab cessation noted.
Conclusions:
- Omalizumab in conjunction with AIT shows promise for allergic rhinitis, venom hypersensitivity, and food allergy.
- This combination therapy may improve treatment, especially for high-risk individuals.
- Further large-scale, placebo-controlled trials are necessary to optimize use and confirm long-term benefits.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
713
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
713
01:19Antiasthma Drugs: Leukotriene Modifiers
721
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
721
02:06Allergic Reactions
29.3K
Overview
29.3K
01:27Allergic Drug Reactions
1.1K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.1K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
689
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
689
01:24Antiasthma Drugs: Methylxanthines
633
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
633